Keeping in mind that EGF-mediated EMT is a common feature in several cancers, the use of Spautin-1 as an EGFR signaling inhibitor may prove a promising novel addition to therapeutic schemes for several cancers, including PCa. The gene discussed is EGFR; the disease is posterior cortical atrophy.